Patient-derived organoids as a predictive biomarker for treatment response in cancer patients

G. Emerens Wensink(Utrecht University), Sjoerd G. Elias(Utrecht University), Jasper Mullenders(Hubrecht Institute for Developmental Biology and Stem Cell Research), Miriam Koopman(Utrecht University), Sylvia F. Boj(Hubrecht Institute for Developmental Biology and Stem Cell Research), Onno Kranenburg(Utrecht University), Jeanine M.L. Roodhart(Utrecht University)
npj Precision Oncology
April 12, 2021
10.1038/s41698-021-00168-1
Cited by 283Open Access
Full Text

Abstract

Effective predictive biomarkers are needed to enable personalized medicine and increase treatment efficacy and survival for cancer patients, thereby reducing toxic side effects and treatment costs. Patient-derived organoids (PDOs) enable individualized tumour response testing. Since 2018, 17 publications have examined PDOs as a potential predictive biomarker in the treatment of cancer patients. We review and provide a pooled analysis of the results regarding the use of PDOs in individualized tumour response testing, focusing on evidence for analytical validity, clinical validity and clinical utility. We identify future perspectives to accelerate the implementation of PDOs as a predictive biomarker in the treatment of cancer patients.

Related Papers

No related papers found

Powered by citation graph analysis